Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep

Abstract

Whole body clearance of atrial natriuretic factor is due to both receptor uptake and enzymatic degradation initiated by neutral endopeptidase 24.11. The effects of neutral endopeptidase inhibition have been studied in seven sodium-replete sheep using SCH 39370, a specific and potent inhibitor of neutral endopeptidase, in the presence or absence of exogenous hormone [rat ANF-(101-126), 2.4 pmol/kg/min for 2 hours]. SCH 39370 alone (2.5 mg/kg bolus) increased plasma atrial natriuretic factor and plasma cyclic GMP levels, lowered arterial pressure for periods beyond changes in plasma atrial natriuretic factor or cyclic GMP, and suppressed both plasma aldosterone and cortisol levels when compared with vehicle injections. The effects of SCH 39370 were similar to or exceeded those of atrial natriuretic factor infusions, which induced significantly greater increases in plasma atrial natriuretic factor (p=0.01). Neither agent alone was natriuretic. When SCH 39370 and atrial natriuretic factor were given together, plasma cyclic GMP but not atrial natriuretic factor levels were increased (p=0.013) compared with atrial natriuretic factor infusion alone, and the half-life was prolonged (p=0.002) in the presence of SCH 39370. The hypotensive response was greater than that induced by atrial natriuretic factor alone (p=0.03) but not different from SCH 39370 alone. Inhibitory effects of SCH 39370 on aldosterone levels were similar in the presence or absence of exogenous atrial natriuretic factor. Although not excluding actions of neutral endopeptidase inhibitors mediated by non-atrial natriuretic factor pathways, these results are consistent with a prolonged effect of neutral endopeptidase inhibition to increase tissue atrial natriuretic factor activity and provide further evidence of the importance of neutral endopeptidase in atrial natriuretic factor physiology.